In a report released yesterday, Brandon Folkes from Cantor Fitzgerald reiterated a Buy rating on Collegium Pharmaceutical (COLL), with a price target of $35. The company’s shares closed yesterday at $15.56.
“. Post 3Q18, we are reiterating our Overweight rating and our 12-month price target of $35. We remain positive on the long-term growth potential of Xtampza, which we expect to be the leading branded extended-release oxycodone over time. We think the company is only in the early stages of building a much-larger portfolio of differentiated opioid and non-opioid pain treatments. Collegium has shown a willingness to work with payers to ensure that the company’s products are available to patients without excessive payer restrictions. Collegium’s lead growth driver is Xtampza, which we continue to believe will replace OxyContin as the largest branded oxycodone ER product.”
According to TipRanks.com, Folkes is a 3-star analyst with an average return of 3.0% and a 47.2% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.
Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $32.
The company has a one-year high of $29.90 and a one-year low of $10.29. Currently, Collegium Pharmaceutical has an average volume of 426.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collegium Pharmaceutical, Inc. engages in the development and commercialization of next-generation, abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases.